Loading clinical trials...

COMPLETED

A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs

Post-marketing Surveillance Study of Viekira/ Exviera Tablets for Korean Hepatitis C Patients According to the Standard for "Re-examination of New Drugs"

NCT03201718•AbbVie

View on ClinicalTrials.gov

Summary

Post-marketing surveillance study to evaluate the real world safety and effectiveness of Viekira/ Exviera (paritaprevir/ritonavir/ombitasvir and dasabuvir) administered under a normal, routine treatment practice by Korean patients with Hepatitis C.

Eligibility

Age

18 - 99 years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Participants with type C hepatitis
•Participants prescribed Viekira/Exviera in accordance with approved local label

Exclusion Criteria

•None

Locations (59)

Dong-A University Hospital /ID# 167362

Busan, Busan Gwang Yeogsi, South Korea

Pusan National University Hosp /ID# 167363

Busan, Busan Gwang Yeogsi, South Korea

Kyungpook National Univ Hosp /ID# 168731

Daegu, Daegu Gwang Yeogsi, South Korea

Yeungnam University Med Ctr /ID# 167425

Daegu, Daegu Gwang Yeogsi, South Korea

Chungnam National University Hospital /ID# 167724

Junggu, Daejeon Gwang Yeogsi, South Korea

National health insurance cooperation ilsan hospital /ID# 201806

Goyang, Gyeonggido, South Korea

Soon Chun Hyang University Hospital Bucheon /ID# 201803

Habun, Gyeonggido, South Korea

Seoul National Univ Bundang ho /ID# 167394

Seongnam, Gyeonggido, South Korea

St. Vincent's Hospital /ID# 201660

Suwon, Gyeonggido, South Korea

Ajou University Hospital /ID# 167729

Suwon, Gyeonggido, South Korea

Key Dates

Start Date

August 17, 2017

Primary Completion Date

October 11, 2019

Completion Date

October 11, 2019

Last Updated

October 8, 2020

Enrollment

505

ACTUAL participants

Conditions

Hepatitis C Virus (HCV)

MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo

NCT07388979

HIV - Human Immunodeficiency VirusHBV (Hepatitis B Virus)+6 more

View study

COMPLETEDPHASE3

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

NCT02219490

Chronic Hepatitis C Virus (HCV) Infection Genotype 1

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: October 8, 2020Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

A Study of Viekira/Exviera for Korean Hepatitis C Patients According to the Standard for Re-examination of New Drugs

Inclusion Criteria

Exclusion Criteria

MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

A Study to Evaluate Long-term Outcomes Following Treatment With ABT-450/Ritonavir/ABT-267 (ABT-450/r/ABT-267) and ABT-333 With or Without Ribavirin (RBV) in Adults With Genotype 1 Chronic Hepatitis C Virus (HCV) Infection

A Study of the Effectiveness and Clinical Practice Use of Glecaprevir/Pibrentasvir in Adolescents With Chronic Hepatitis C Genotypes 1 to 6 in Russian Federation

Efficacy and Safety of Elbasvir (MK-8742) + Grazoprevir (MK-5172) in Treatment-Naïve/Treatment-Experienced (TN/TE) French Participants With Hepatitis C Virus (HCV) Genotype 4 (GT4) Infection (MK-5172-096)

A Study to Evaluate the Efficacy and Safety of Glecaprevir/Pibrentasvir (ABT-493/ABT-530) in Treatment-Naive and Treatment-Experienced, Non-Cirrhotic Asian Adults With Chronic Hepatitis C Virus Genotype (GT) 1 to GT6 Infection With or Without Human Immunodeficiency Virus Co-Infection